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Abstract 12 
Although the use of low-calorie sweeteners (LCSs) is widespread, methods of assessing 13 
consumption within free-living populations have inherent limitations. Five commonly consumed 14 
LCSs, namely acesulfame-K, saccharin, sucralose, cyclamate and steviol glycosides are excreted 15 
via the urine and therefore a urinary biomarker approach may provide more objective LCS intake 16 
data. A LC-ESI-MS/MS method of simultaneously determining acesulfame-K, saccharin, 17 
sucralose, cyclamate and the excretory metabolite of steviol glycosides, steviol glucuronide, in 18 
human urine was developed and validated. Linearity was observed over a concentration range of 19 
10-1000 ng/ml with coefficients of determination ranging from 0.9969 to 0.9997. Accuracy ranged 20 
from 92 to 104% and intra-batch and inter-day precision were within acceptable limits with % CV 21 
below 8% for all compounds. A double-blind, randomized cross-over dose-response study was 22 
conducted to assess the usefulness of urinary LCS excretions (from both fasting spot and a full 24-23 
hour urine collection) for investigating recent intakes. Both modes of sampling were useful for 24 
distinguishing between the three short-term intakes of acesulfame-K, saccharin, cyclamates and 25 
steviol glycosides (p < 0.001) while for sucralose, urinary concentrations were useful for 26 
distinguishing between low (0.1% ADI) and high doses (10% ADI) only (p < 0.001). In summary, 27 
this biomarker approach may be useful for assessing intakes of five commonly consumed LCSs. 28 
Keywords: low-calorie sweeteners; intense sweeteners; biomarkers; urinary biomarkers; 29 
exposure; food additives; human urine.  30 
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Introduction 31 
The prevalence of obesity, a major risk factor for the development of chronic conditions such as 32 
cardiovascular disease, type 2 diabetes mellitus and hypertension,1 has increased significantly over 33 
recent decades.2-4 Although its cause at the population level is multi-factorial,1 central to its 34 
occurrence at the individual level are lifestyles characterized by sedentary behaviors and unhealthy 35 
dietary practices. One dietary practice that has been implicated in contributing to overweight and 36 
obesity, as well as other adverse health outcomes, is the over-consumption of free sugars, 37 
particularly from sugar-sweetened beverages.5,6 As such, recently published guidelines 38 
recommend that intakes of free sugars should not exceed 5%6 or 10%5 of total energy intake. Given 39 
that current free sugar intakes within the population largely exceed these recommendations,6 40 
strategies that support a reduction in intake, while maintaining diet palatability, include the 41 
substitution of free sugars with low-calorie sweeteners (LCSs).  42 
LCSs are a chemically diverse group of intensely sweet, low energy, food additives that are non-43 
cariogenic7 and used in a wide range of dietary and non-dietary products to provide a desired sweet 44 
taste without increasing energy density or inducing adverse oral health outcomes. Intuitively, LCSs 45 
should be expected to offer health benefits when used in place of free sugars; indeed, a recent 46 
meta-analysis of RCTs (sustained over 4 weeks to 40 months) indicated that LCS consumption 47 
versus sugar led to reductions in body weight.8 Despite such health benefits, debate around their 48 
long-term efficacy continues, particularly in relation to weight management,9 type 2 diabetes10,11 49 
and other metabolic effects.12 A number of mechanisms by which LCSs may adversely impact on 50 
health have been discussed and while a number of these putative mechanisms have been supported 51 
by some animal data, none have yet been demonstrated in humans.13 Observational data, in 52 
particular, have been conflicting in relation to the health effects of LCSs, as highlighted in a recent 53 
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review of the evidence by the French Agency for Food, Environmental and Occupational Health 54 
and Safety (ANSES);14 however a major limitation of most cohort studies is that only low-calorie 55 
sweetened beverage (LCSB) consumption is considered when investigating associations between 56 
LCSs and health. LCSs are ubiquitous in today’s society and LCSBs are only one of many sources 57 
of LCSs in the diet; indeed, some LCSs have recently been identified as potential environmental 58 
contaminants and detected in drinking-water sources15 so exposure to some LCSs may actually 59 
occur inadvertently in certain populations. Furthermore, intakes of individual LCSs are very rarely 60 
estimated in cohort studies,14 impairing the ability to properly explore relationships between these 61 
chemically diverse food additives and health. This is further compounded by the fact that blends 62 
of LCSs are now often used within the same product. With these factors in mind, conclusions 63 
drawn from current observational data are likely to be tenuous and therefore, an alternative 64 
approach which provides more objective and specific LCS intake data would be highly desirable 65 
in order to enhance research in the area of LCSs and human health. 66 
A nutritional biomarker approach involving the measurement of components of the diet, or their 67 
metabolites, as indicators of intake may offer an opportunity to more objectively and specifically 68 
assess intakes of LCSs and therefore address a number of fundamental limitations with some 69 
current research approaches into the health impacts of LCS use. Such an approach has previously 70 
been utilized for investigating intakes of other dietary components such as salt, protein and 71 
wholegrains.16,17 A number of LCSs, once absorbed into the body, are excreted via the urine 72 
following little or no metabolism.18 Urinary excretions of acesulfame-K and saccharin were 73 
previously investigated as potential biomarkers of intakes and were found to be useful.19 Of the 74 
other commonly used LCSs, sucralose and cyclamate may also be suitable for a urinary biomarker 75 
approach as the absorbed proportion is excreted largely unchanged via the urine.18,20 Steviol 76 
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glycosides, in contrast, undergo bacterial hydrolysis to steviol in the large intestine and, following 77 
absorption, are excreted in the urine as steviol glucuronide;21 as such, this metabolite may prove 78 
to be a useful biomarker of intake. To determine the feasibility of such a biomarker approach, it is 79 
first necessary to develop a suitable and reliable analytical method for measuring the compounds 80 
of interest.22,23 One of the most commonly reported techniques for simultaneously analyzing LCSs 81 
in foods, beverages, and in water samples, is liquid chromatography with mass spectrometry using 82 
electrospray ionization (LC-ESI-MS/MS).15,24-27 Validation of the biomarker should also be 83 
conducted to characterize the relationship between the candidate marker and the dietary 84 
component of interest.28 85 
The present work consisted of two studies with distinct aims: firstly, to develop and validate a LC-86 
ESI-MS/MS method of simultaneously determining acesulfame-K, saccharin, sucralose and 87 
cyclamate and steviol glucuronide in human urine and secondly, to assess whether urinary 88 
excretions of these compounds are useful for investigating short-term intakes of the respective 89 
LCS. It was hypothesized that urinary excretions of the compounds of interest would be useful for 90 
distinguishing between three levels of intake relevant to the free-living population. 91 
Materials and Methods 92 
Method development and dose-response studies 93 
Reagents and reference materials 94 
High performance liquid chromatography (HPLC) grade water and HPLC grade methanol were 95 
purchased from Fisher Chemicals (Loughborough, UK). Ammonium carbonate, along with 96 
acesulfame-K, sodium saccharin, sodium cyclamate and sucralose, were purchased from Sigma-97 
Aldrich (St. Louis, MO, USA). Steviol glucuronide (96.4% purity by HPLC) was kindly supplied 98 
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by The Coca-Cola Company (Atlanta, US). Acesulfame-d4 potassium salt (Ace-d4), sucralose-d6 99 
(Suc-d6) and saccharin-d4 (Sac-d4) were purchased from Toronto Research Chemicals Inc. 100 
(Toronto, Canada) while sodium cyclamate-d11 (Cyc-d11) and warfarin sodium were purchased 101 
from QMX Laboratories (Thaxted, UK) and Sigma-Aldrich (St. Louis, MO, USA) respectively. 102 
All reference materials were of analytical standard. 103 
Individual stock solutions of 1 mg/ml were prepared in water/methanol (50:50) for acesulfame-K, 104 
sodium saccharin, sodium cyclamate, sucralose and steviol glucuronide and from these, a working 105 
solution containing all five compounds at concentrations of 0.1 mg/ml was prepared in 106 
water/methanol (50:50) and stored at 4 0C. For the internal standards (IS), individual stock 107 
solutions of 1 mg/ml were prepared in methanol for Ace-d4, Sac-d4 and Suc-d6. Warfarin sodium 108 
and Cyc-d11 were dissolved in water/methanol (50:50) at concentrations of 80 µg/ml and 40 µg/ml 109 
respectively. Prior to each batch, a working solution containing 5 µg/ml Ace-d4, Sac-d4, Suc-d6 110 
and 4 µg/ml and 2 µg/ml warfarin sodium and Cyc-d11 respectively was prepared in mobile phase 111 
A (MP-A) (see below for MP-A composition). 112 
Boric acid, purchased from Sigma-Aldrich (St. Louis, MO, USA), was used as a preservative in 113 
urine samples by adding 10 g to each 3 liter container. Completeness of 24-hour urine collections 114 
was assessed using the paraminobenzoic acid (PABA) method.29 During each 24-hour urine 115 
collection period, participants were asked to consume one tablet containing 80 mg PABA at three 116 
specified times (8am, 12pm and 6pm; 240 mg in total) and a recovery of at least 187 mg (78% of 117 
the dose) signified a complete sample.30 PABA tablets were purchased from the Medical Research 118 
Council (Cambridge, UK). If participants forgot to take all three PABA tablets yet reported 119 
collecting a complete 24-hour sample, the urine sample was also considered complete. 120 
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Instrumentation 121 
Method development and validation was conducted on a HPLC-MS system consisting of a Thermo 122 
Separation Products HPLC system (Waltham, US) interfaced with a QTrap 3200 hybrid 123 
quadrupole-linear ion trap mass spectrometer (AB Sciex, Warrington, UK). Urine analysis in the 124 
dose-response study was conducted on a HPLC-MS system consisting of a Shimadzu UHPLC 125 
system (Milton-Keynes, UK) and an API 4000 triple quadrupole mass spectrometer (AB Sciex, 126 
Warrington, UK) following method transfer and optimization of MS conditions.  127 
Method development and validation 128 
Collection of LCS-free urine samples for method development 129 
Twelve apparently healthy volunteers (6 females; 6 males; age range, 21-51 years) were recruited 130 
to provide blank urine samples for the purposes of method development and validation.  Those 131 
with diabetes, renal impairment, taking or planning to take sulfonamide antibiotics during the study 132 
or with lactose intolerance were excluded from the study. Participants were asked to avoid foods 133 
and beverages known to contain acesulfame-K, saccharin, cyclamate, sucralose and steviol 134 
glycosides for a period of at least three days prior to collecting a 24-hour urine sample. To aid this, 135 
verbal advice and literature were provided to each participant. From each sample, ten 1 ml aliquots 136 
and two 30 ml aliquots were retained and stored at -80 0C for later use in method development. 137 
Ethical approval was granted for this method development study by the Ulster University 138 
Biomedical Sciences Research Ethics Filter Committee (Study No: FCBMS-13-058). 139 
Calibration and Quality Control samples 140 
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All urine samples (n = 12) were screened for the presence of the compounds of interest and those 141 
found with no or negligible concentrations (n = 6), were used for the purposes of method 142 
development and validation. Calibration and quality control (QC) samples were prepared by 143 
fortifying blank urine samples with known concentrations of the compounds of interest. 144 
For the preparation of calibration standards, fortification solutions at concentrations of 1.0, 12.5, 145 
25.0, 37.5, 50.0, 75.0 and 100.0 µg/ml were prepared from the respective LCS working solution. 146 
Fortification solutions were also prepared at concentrations of 12.5, 55.0 and 93.0 µg/ml and these 147 
were used for the preparation of QC samples which were run during each batch. Fortification of 148 
the blank urine samples resulted in a 10-fold dilution of these concentrations. 149 
Sample preparation  150 
A simple preparation procedure was used in which fortified urine samples underwent a further 10-151 
fold dilution and were filtered. Each sample was vortexed for a minimum of 10 seconds to ensure 152 
homogenization and 100 µl was mixed with 20 µl of IS working solution in a 1.5 ml tube and made 153 
up to 1 ml using MP-A (see below for composition of MP-A). The mixture was again vortexed for 154 
a minimum of 10 seconds and filtered using a 0.22 µm mixed cellulose ester filter membrane 155 
(Merck KGaA, Darmstadt, Germany). From the filtrate, 100 µl was retained for analysis. 156 
Liquid chromatography-tandem mass spectrometry conditions 157 
Separation was accomplished using a Poroshell 120 EC-C18 (4.6 x 50 mm), 2.7 µm column 158 
equipped with a Poroshell 120 UHPLC EC-C18 guard column (Agilent Technologies, Santa Clara, 159 
US). HPLC conditions from an Agilent Technologies application note31 were adapted for the 160 
purposes of this method. Flow rate was maintained at 0.6 ml/min throughout and a binary gradient 161 
program was used. MP-A consisted of 2 mM ammonium carbonate in water/methanol (95/5%) 162 
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(pH 8.8) and mobile phase B (MP-B) consisted of 2 mM ammonium carbonate in methanol (pH 163 
8.9). The gradient program was as follows: 0 min, 100% A, 7.0 min, 25% A, 9.0 min, 25% A, 9.1-164 
15.0 min, 100% A. Sample injection volume was 20 µl and the needle was flushed with 500 µl of 165 
a water/methanol (60/40%) solution following each injection. Column temperature was 166 
maintained at 30 0C throughout using an integrated column oven. 167 
The mass spectrometer was equipped with a Turbo-V ion source and ESI was operated in negative 168 
polarity with multiple reaction monitoring (MRM) scan mode used for detection. Scheduled 169 
scanning for specific compounds was carried out according to the expected time of elution, thus 170 
improving sensitivity and precision. Nitrogen gas, supplied by a Peak Scientific gas generator, was 171 
used as nebulizer, collision and desolvation gas. The two most intense MRM transitions were 172 
identified and compound specific parameters including declustering potential, collision energy and 173 
collision cell exit potential were optimized by directly infusing each compound at concentrations 174 
of 1 µg/ml in methanol into the mass spectrometer. Ion source parameters for each compound were 175 
optimized using flow injection analysis with the aim of maximizing signal intensity and stability. 176 
The source temperature was set at 600 0C and gas sources 1 and 2 were set at 35 psi and 40 psi 177 
respectively. Ion spray voltage was -4.5 kv and curtain gas was set at 40 psi. 178 
Method validation  179 
Method validation was conducted by assessing method performance in relation to linearity, limits 180 
of detection (LOD), lower limits of quantification (LLOQ), precision and accuracy, and finally 181 
matrix effects (ME). Linearity was assessed across a concentration range of 10-1000 ng/ml by 182 
generating eight-point calibration curves for each compound of interest. The ratios of the peak 183 
areas of the target analytes and their corresponding IS were plotted versus concentration following 184 
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duplicate analysis and a weighting of 1/x was applied owing to the large working range. LOD and 185 
LLOQ, defined as signal to noise ratio of 3:1 and the lowest concentration of the linear regression 186 
respectively,32 were assessed after conducting duplicate analysis of blank urine samples fortified 187 
to concentrations ranging from 0.001-5ng/ml. Precision and accuracy were assessed at three 188 
concentrations within the working range; 12.5 ng/ml (low), 550 ng/ml (medium) and 930 ng/ml 189 
(high) for all five compounds. Intra-batch precision was assessed by calculating the % co-efficient 190 
of variation (% CV) following six repetitions at each concentration. Accuracy was assessed by 191 
calculating the mean % accuracy of the same samples. To assess inter-day precision, % CV were 192 
calculated following six repetitions at each concentration on six days over a three week period. 193 
ME, a commonly observed source of error in LC-ESI-MS/MS bioanalysis, were assessed by 194 
comparing the analyte peak areas of a neat solution containing 500 ng/ml of each analyte with 195 
those of urine samples, obtained from six different volunteers and fortified to the same 196 
concentrations. The % ME were then calculated as: 197 
% ME =  100 × (
𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑓𝑜𝑟𝑡𝑖𝑓𝑖𝑒𝑑 𝑢𝑟𝑖𝑛𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑛𝑒𝑎𝑡 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
) 198 
Stability 199 
The optimal mode of sampling in the application of a biomarker approach for assessing LCS 200 
intakes may involve the collection of 24-hour urine samples and therefore samples are likely to be 201 
kept in potentially sub-optimal storage conditions for longer periods of time prior to final storage 202 
and subsequent analysis. Therefore, the stability profiles of the compounds of interest was assessed 203 
over a period of 72-hours. To do this, two 1.5 ml aliquots of blank urine samples were fortified to 204 
approximately 500 ng/ml with each of the five compounds of interest and transferred to two amber 205 
glass vials. Both were stored in the dark with one sample stored at room temperature while the 206 
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other was kept refrigerated at 4 0C. Aliquots of each sample were taken at five time-points (0, 18, 207 
24, 48 and 72 hours) and stored at -80 0C until analysis. 208 
Dose-response study 209 
A double-blind, randomized crossover trial was conducted to assess the usefulness of using urinary 210 
excretions to distinguish between different short-term intakes of the five LCSs. A total of 21 211 
participants were recruited to the study. Participation lasted three weeks, during which participants 212 
were asked to consume three doses of the five LCSs via water-based drinks and to collect both a 213 
fasting spot and 24-hour urine sample during each dosing period. The study was approved by the 214 
Ulster University Research Ethics Committee (Study No. BMS 014-0095) and a comprehensive 215 
description of the study protocol can be found within the supplementary information. 216 
In brief, participants’ height and weight were measured and they were asked to avoid all of the 217 
LCS of interest from at least three days prior to commencing the study to completion, again 218 
receiving written literature and verbal advice to aid this. Three doses of the five LCSs of interest, 219 
representing 0.1% (low), 0.5% (medium) and 10% (high) of the respective acceptable daily intake 220 
(ADI) based on a 70 kg person, were consumed in a randomized order via two water-based drinks. 221 
These doses are relevant to intakes within the free-living population.33 Randomization (using 222 
Sealed Envelope™) and blinding (by labelling each dose A, B or C) was conducted by a local 223 
clinical trials manager who was not part of the current research team. The drinks (500 ml each) 224 
were consumed over two consecutive days at specified times during the three week period and, to 225 
blind participants to the dose, 75 ml of an orange cordial (Sainsbury’s, UK) was added to each 226 
drink during preparation. Participants were purposely advised to consume the test drinks as they 227 
preferred across the day to reflect consumption patterns in free-living individuals as much as 228 
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possible, with the only stipulation that they consumed one drink (500 ml) per 24-hour period. On 229 
the second day of each dosing period, participants collected a morning fasting spot urine sample 230 
and a 24-hour urine sample and returned these to the university.  231 
All urine samples were processed within two hours of receipt and stored at -80 0C until analysis. 232 
Urinary biomarker analysis was carried out as described above and PABA analysis was carried 233 
out to assess completeness of the 24-hour urine samples as described elsewhere.30 To standardize 234 
LCS concentrations in fasting spot urine samples, creatinine concentrations were determined using 235 
an ILab 650 (Instrumentation Laboratories, Massachusetts, USA). 236 
Statistical analysis 237 
All data related to method development and validation were acquired and statistically analyzed 238 
using Analyst Software Version 1.4.2 (AB Sciex, Warrington, UK) while statistical analysis of the 239 
dose-response data was performed using the Statistical Package for Social Sciences (SPSS) 240 
Version 22.0 (SPSS UK Ltd, Chersey, United Kingdom). Total LCS excretions were calculated 241 
by multiplying the 24-hour urinary concentrations (mg/ml) by the volume of the total sample (ml) 242 
and expressed as mg/day. Creatinine concentrations in fasting spot urine samples were used to 243 
standardize LCS concentrations and values were expressed as µg/g creatinine. Steviol glycosides 244 
are excreted via the urine as steviol glucuronide and therefore values were converted to steviol 245 
equivalents; therefore, based on their molecular weights, factors of 0.643 and 0.39 were applied to 246 
steviol glucuronide and steviol glycoside values respectively. 247 
The distribution of continuous data was assessed using the Shapiro-Wilk test and data which were 248 
not normally distributed were log-transformed or non-parametric alternatives were employed. 249 
Urinary excretions of all LCSs were skewed and therefore transformation of the data was attempted 250 
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prior to carrying out statistical analysis. It was not possible to normalize the distribution of the 251 
data; therefore Freidman Tests were used to assess mean differences in excretions across all 252 
treatments. Statistically significant results were followed up with Wilcoxon Signed Rank Tests to 253 
identify where the differences were. Bonferroni adjustment was applied to the alpha values in post-254 
hoc Wilcoxon Signed Rank Tests to control for Type 1 errors as a result of multiple comparisons 255 
and therefore an alpha level of 0.017 (0.05/number of comparisons) was considered significant. 256 
Spearman correlations were carried out to assess co-linearity between the dose of LCS ingested 257 
and urinary excretions (both 24-hour urine and fasting spot sample). Standard multiple regression 258 
was then used to assess the ability of 24-hour urinary excretion of the five compounds of interest 259 
to predict intake after controlling for age, gender and body mass index (BMI). A P-value of <0.05 260 
was considered statistically significant unless otherwise stated. 261 
Results and Discussion 262 
Improved assessment of LCS intakes is necessary to properly investigate relationships between 263 
LCS use and health. To this end, a LC-ESI-MS/MS method was developed and validated for the 264 
simultaneous determination of five commonly used LCSs in human urine. Although numerous 265 
methods have been published describing the simultaneous determination of various combinations 266 
of LCSs in matrices such as foods, beverages and water sources,15,24-27 the method described here 267 
is the first which simultaneously determines these particular LCSs as they are excreted via urine. 268 
As an initial biomarker validation step, the method was applied in a dose-response study to assess 269 
the usefulness of using urinary excretions to assess recent intakes. 270 
Method performance 271 
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The general characteristics, including the chemical structures of the five compounds of interest, 272 
are presented in Table 1. Single spectral peaks corresponding to [M-K]- for acesulfame-K, [M-273 
Na]- for sodium saccharin and sodium cyclamate and [M-H]- for sucralose and steviol glucuronide 274 
were observed. Table 2 presents the two MRM transitions used for quantitative and qualitative 275 
purposes, the corresponding IS and the collision energy for each MRM transition. The most intense 276 
transition for each compound was used for quantification. In contrast to a previous study by Yang 277 
and Chen,34 which utilized MS only, the utilization of MS/MS in this study allowed for increased 278 
specificity and sensitivity which is important in bioanalysis.  As has been reported elsewhere in 279 
the literature, the signal intensity for sucralose was lower than for the other analytes and post-280 
column infusion of TRIS-buffer has previously been used to enhance the signal for sucralose.24 281 
However for the purposes of our method, and the desired working range, the signal was deemed 282 
adequate without the need for further enhancement. 283 
Good base peak separation was observed for the five compounds (Fig. 1). Previous methods have 284 
incorporated solid phase extraction24,26 or liquid-liquid extraction34 in sample preparation which 285 
may make the application of such methods less feasible for large numbers of samples, whereas the 286 
simple procedure described above lends itself better to a high throughput application. However, 287 
with minimal sample clean-up prior to introduction to the mass spectrometer, the integrated 288 
diverter valve was used to direct flow to waste outside the expected elution times and thereby 289 
protecting the mass spectrometer from excessive contamination. Various concentrations of 290 
methanol (2-15%) in MP-A were assessed and when the concentration was increased to 10% or 291 
above acesulfame-K eluted close to the void volume; therefore 5% was considered suitable. 292 
Method validation 293 
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Results for linearity, LOD and LLOQ, and precision and accuracy are presented in Table 2. 294 
Excellent linearity was observed for all five compounds over the desired concentration range of 295 
10-1000 ng/ml with coefficients of determination (r2) ranging from 0.9969 to 0.9997. Mean 296 
accuracy ranged from 98% to 104% at low concentrations while at high concentrations, accuracy 297 
ranged from 92% to 102%. The use of stable isotopes as IS for acesulfame-K, sodium saccharin, 298 
sodium cyclamate and sucralose resulted in excellent levels of accuracy (99-103%) and precision 299 
with % CV below 7.7% at all three concentrations assessed (i.e. 15 ng/ml, 550 ng/ml and 930 300 
ng/ml). For steviol glucuronide, warfarin sodium was used as IS as this has been previously used 301 
for LC-MS analysis of LCSs.34 Accuracy and precision for steviol glucuronide fell within 302 
acceptable limits, albeit the use of the stable isotope of this compound as IS in future analyses 303 
would likely improve these figures further. 304 
Prior to the assessment of the presence of ME, screening of ‘blank’ urine samples revealed traces 305 
of several of the compounds of interest and therefore duplicate runs of all six samples were carried 306 
out prior to analysis of the fortified samples so that corrections could be applied. The average area 307 
of each observed peak in the pre-fortified samples was recorded and the results were subsequently 308 
corrected. Mean % ME ranged from 89% to 99% for acesulfame-K, 80% to 100% for saccharin, 309 
89% to 104% for cyclamate, 87% to 99% for sucralose and 94% to 107% for steviol glucuronide. 310 
These results suggest the existence of interfering compounds within some urine samples, 311 
potentially introducing a source of inaccuracy and/or imprecision if neat solutions were used as 312 
calibration and QC standards. However, with the use of IS, % CV within urine samples were below 313 
5.5% for all five compounds and therefore all calibration and QC samples were prepared using 314 
blank urine samples. As such, the potentially deleterious effects of ME were largely minimized. 315 
Stability 316 
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Acesulfame, saccharin, cyclamate and sucralose have recently been identified as potential aquatic 317 
contaminants owing to their persistence in the environment23 and therefore good stability was 318 
expected over the 72-hour test period. However the stability profile of steviol glucuronide was less 319 
well known. Indeed, acesulfame-K, saccharin, cyclamate and sucralose did not undergo any 320 
detectable degradation over the 72-hour period either when stored at room temperature or when 321 
refrigerated. A small, yet non-significant (p = 0.312), degree of degradation (~8%) was observed 322 
for steviol glucuronide when stored at room temperature for up to 72-hours. 323 
Dose-response study 324 
Participants and urine collections 325 
No significant differences were observed between males and females with respect to age, weight, 326 
BMI or volume of 24-hour urine samples (Table 3). During the dose-response study, participants 327 
consumed three different amounts (0.1%, 0.5% and 10% of the ADI based on a 70 kg person) of 328 
the five LCSs comparable to what has been observed within the free-living population,22,33 while 329 
avoiding the five LCSs in their diet. A total of 84 24-hour urine samples were collected (four per 330 
participant) and of these, 55 (65.5%) were considered complete based on PABA excretion and/or 331 
participant reporting. Mean urinary concentrations (based on fasting spot samples) and daily 332 
excretion (based on 24-hour samples) following each dosing period are presented in Table 4. 333 
Biomarker validation 334 
Mean urinary concentrations of all five compounds were significantly correlated with intakes of 335 
the respective LCS; the correlations for 24-hour urinary acesulfame-K, saccharin, cyclamate, 336 
sucralose and steviol glucuronide were 0.909 (p < 0.001), 0.888 (p < 0.001), 0.942 (p < 0.001), 337 
0.512 (p = 0.001) and 0.942 (p < 0.001) respectively. Correlations for fasting spot urinary 338 
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concentrations of acesulfame-K, saccharin, cyclamate, sucralose and steviol glucuronide were 339 
0.823 (p < 0.001), 0.874 (p < 0.001), 0.818 (p < 0.001), 0.410 (p = 0.007) and 0.887 (p < 0.001) 340 
respectively. Until now, the dose-response relationship between intake and urinary excretion has 341 
only been investigated for acesulfame-K and saccharin when strong correlations were also 342 
observed between 24-hour urinary excretion and intakes (r2 = 0.9912 for acesulfame-K and r2 = 343 
0.9963 for saccharin) during an acute intake/excretion study.19 344 
In relation to 24-hour urine samples, mean recoveries from the low, medium and high doses were 345 
98%, 89% and 85% for acesulfame-K, 100%, 79% and 86% for saccharin, 24%, 28% and 25% for 346 
cyclamate and 86%, 52.7% and 47% for steviol glycosides (see Table 4 for absolute recoveries). 347 
Higher than expected levels of recovery of sucralose were observed at the lower doses (450%, 348 
100% for low and medium respectively) as it was present in the cordial used in the LCS drinks 349 
and this is discussed in more detail later. For the high dose of sucralose, mean recovery was 8 % 350 
while previous work investigating the pharmacokinetics of sucralose reported an average excretion 351 
of 13% of a dose in urine within the first 24-hours post-ingestion.20 For acesulfame-K and 352 
saccharin the majority of the dose was recovered which is in agreement with results reported 353 
elsewhere,35-37 although one study reported an average recovery of 68% of an acesulfame-K dose 354 
in 24-hour urine samples.19 In contrast to acesulfame-K and saccharin, only partial recoveries were 355 
observed in the 24-hour urinary samples for cyclamate (24-28%) and steviol glycosides (47-86%). 356 
Previous pharmacokinetic investigations of cyclamate primarily focused on its metabolite, 357 
cyclohexylamine, as approximately 20% of the population have the ability, to varying degrees, to 358 
convert cyclamate to cyclohexylamine via bacterial hydrolysis. Chronic exposure has been shown 359 
to enhance conversion in some individuals;38 however, conversion only occurs to the unabsorbed 360 
proportion reaching the colon and therefore does not affect the absorbed proportion of cyclamate.39 361 
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Steviol glycosides also undergo bacterial hydrolysis in the gut and are absorbed into the body as 362 
steviol which subsequently undergoes conjugation before excretion via the urine as steviol 363 
glucuronide.40 Previously it has been reported that approximately 34% of a dose is excreted in the 364 
urine over 24-hours41 which is much lower than what was observed as part of this work which 365 
observed typical excretion of 47-86% over the same period. A possible explanation is the dose in 366 
the previous study was significantly larger than in the present work.  367 
Both modes of sampling were useful for distinguishing between all three intakes tested in the 368 
present study for acesulfame-k (p < 0.001), saccharin (p < 0.001), cyclamate (p < 0.001) and steviol 369 
glycosides (p < 0.001) (Table 4). It is particularly noteworthy that fasting spot urine samples are 370 
useful as the collection of such samples would be less invasive for participants, making the 371 
application of a biomarker approach in larger-scale population based studies more feasible. 372 
However, further validation work with a larger sample size would help to confirm the usefulness 373 
of fasting spot samples for distinguishing between different intakes. In relation to sucralose, it was 374 
possible to use both the fasting spot and 24-hour urinary sucralose excretions to distinguish the 375 
high dose from both the low and medium doses (p < 0.001) but not the low and medium doses (p 376 
= 0.198). The presence of sucralose in the cordial used for the LCS drinks is likely to have biased 377 
the results at the lower doses and therefore further work, with proper wash-out periods, would 378 
facilitate more comprehensive investigations of the dose-response relationship for sucralose. 379 
Given that 24-hour urinary excretions allow for calculation of overall daily excretion, regression 380 
analysis using the LCS dose as a dependent variable and 24-hour urinary concentrations as an 381 
independent variable were conducted and 24-hour excretions explained 99% of the variability for 382 
acesulfame-K (F (1, 39) = 2302.32, adjusted r2 = 0.987, p < 0.001), 87% of the variability for 383 
saccharin (F (1, 39) = 261.75, adjusted r2 = 0.870 p < 0.001), 91% of the variability for cyclamate 384 
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(F (1, 39) = 419.23, adjusted r2 = 0.913 p < 0.001), 35% of the variability for sucralose (F (1, 39) 385 
= 22.59, adjusted r2 = 0.350 p < 0.001) and 75% of the variability for steviol glycosides (F (1, 39) 386 
= 118.09, adjusted r2 = 0.745 p < 0.001). Such findings would suggest that 24-hour urinary 387 
excretions may be useful for estimating absolute intakes of the respective LCS. 388 
A number of limitations with the present work should be acknowledged. The presence of sucralose 389 
in the cordial used in the LCS drink prevented a comprehensive investigation of the relationship 390 
between sucralose consumption and urinary excretion. The cordial was chosen as no LCS-free 391 
cordial could be sourced at the time of conducting the study and therefore measures were taken to 392 
control for this by maintaining a consistent dose of cordial added to the LCS drink. However, no 393 
account was taken of the possible variation in sucralose concentrations within the product which 394 
may have contributed to variation in the results. Despite the presence of sucralose in the cordial, a 395 
high intake of sucralose was shown to result in higher mean excretions as compared with the low 396 
or medium intakes in both modes of sampling; as such, urinary excretions of sucralose may be 397 
useful in distinguishing between low and high consumers which, nevertheless, may be of most 398 
clinical interest. A further consideration is that the present studies only investigated urinary 399 
concentrations following short-term intakes (over two consecutive days) and in individuals who 400 
were actively avoiding LCSs. Further work to assess the usefulness of a biomarker approach in 401 
regular and potentially high LCS consumers, such as those with diabetes mellitus or children, is 402 
warranted. Moreover, investigations of the long-term reproducibility of these biomarkers, 403 
specifically aiming to establish the required number of samples to determine habitual intakes are 404 
warranted to better characterize the relationship between intakes and urinary excretions. 405 
A novel urinary biomarker approach for assessing recent intakes of five commonly consumed 406 
LCSs has been presented. Such an approach will help generate more objective LCS intake data 407 
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when applied in population-based studies, representing an opportunity to significantly enhance our 408 
understanding of the relationship between LCSs and human health. 409 
Abbreviations used 410 
Ace-d4, acesulfame-d4 potassium salt; ADI, acceptable daily intake; Cyc-d11, cyclohexyl-d11; 411 
ESI, electrospray ionization; EU, European Union; FFQs, food frequency questionnaires; HPLC, 412 
high performance liquid chromatography; IS, internal standard; LCS, low-calorie sweetener; LC-413 
ESI-MS/MS, liquid chromatography tandem-mass spectrometry; LC-MS, liquid chromatography 414 
mass spectrometry; MRM, multiple reaction monitoring; PABA, paraminobenzoic acid; Sac-d4, 415 
saccharin-d4; Suc-d6, sucralose-d6. 416 
Acknowledgement 417 
We would like to thank Eddie O'Kane for technical assistance throughout method development. 418 
Supporting information description 419 
The Supporting Information is available free of charge on the ACS Publications website at DOI: 420 
xxxx 421 
Description of the dose-response study protocol; the doses administered to participants in the dose-422 
response study (Table S-1). 423 
Funding 424 
This work was funded by the National Institute for Public Health and the Environment (RIVM) in 425 
The Netherlands.  426 
21 
 
References 427 
1. Butland, B.; Jebb, S.; Kopelman, P.; McPherson, K.; Thomas, S.; Mardell, J.; Parry, V.; 428 
Foresight, Tackling Obesities: Future Choices- Project Report; 2nd Edition; UK 429 
Government for Science, 2007. 430 
2. Finucane, M. M.; Stevens, G. A.; Cowan, M. J.; Danaei, G.; Lin, J. K.; Paciorek, C. J.; 431 
Singh, G. M.; Gutierrez, H. R.; Lu, Y.; Bahalim, A. N.; Farzadfar, F.; Riley, L. M.; Ezzati, 432 
M. National, regional, and global trends in body-mass index since 1980: systematic 433 
analysis of health examination surveys and epidemiological studies with 960 country-years 434 
and 9.1 million participants. Lancet. 2011, 377, 557-567.  435 
3. Fryar, C.D.; Carroll, M.D.; Ogden, C.L. Prevalence of Overweight, Obesity, and Extreme 436 
Obesity among Adults: United States, 1960-1962 through 2011-2012; National Center for 437 
Health Statistics, Division of Health and Nutrition Examination Surveys. [Online] 2014, 438 
http://www.cdc.gov/nchs/data/hestat/obesity_adult_11_12/obesity_adult_11_12.htm 439 
(accessed March 4, 2015).  440 
4. World Health Organisation. Obesity and Overweight Fact sheet No 311. WHO Media 441 
Centre [Online] 2015, http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 442 
May 15, 2015). 443 
5. World Health Organisation Guideline: Sugars intake for adults and children. [Online] 2015, 444 
http://apps.who.int/iris/bitstream/10665/149782/1/9789241549028_eng.pdf (accessed 445 
October 2, 2016). 446 
6. Scientific Advisory Committee on Nutrition (SACN) (2015) Carbohydrates and Health. 447 
[Online] 2015, 448 
22 
 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/445503/S449 
ACN_Carbohydrates_and_Health.pdf (accessed January 11, 2016). 450 
7. Grenby, T.H. Update on low-calorie sweeteners to benefit dental health. Int. Dent. J. 1991, 451 
41, 217-224. 452 
8. Rodgers, P. J.; Hognkamp, P. S.; de Graaf, C.; Higgs, S.; Lluch, A.; Ness, A. R.; Penfold, 453 
C.; Perry, R.; Putz, P.; Yeomans, M. R.; Mela, D. J. Does low-energy sweetener 454 
consumption affect energy intake and body weight? A systematic review, including meta-455 
analyses, of the evidence from human and animal studies. Int. J. Obes. 2016, 40, 387-394. 456 
9. Swithers, S. E. Artificial sweeteners produce the counterintuitive effect of inducing 457 
metabolic derangements. Trends Endocrinol. Metab. 2013, 24, 431-441 458 
10. Imamura, F.; O’Connor, L.; Ye, Z.; Mursu, J.; Hayashino, Y.; Bhupathiraju, S. N.; Forouhi, 459 
N. G. Consumption of sugar sweetened beverages, artificially sweetened beverages, and 460 
fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and 461 
estimation of population attributable fraction. Br. J. Sports Med. 2016, 50, 496-504. 462 
11. Romo-Romo, A.; Aguilar-Salinas, C. A.; Brito-Córdova, G.; Gómez Díaz, R. A.; Valentin 463 
D. V.; Almeda-Valdes, P. Effects of non-nutritive sweeteners on glucose metabolism and 464 
appetite regulating hormones: Systematic review of observational prospective studies and 465 
clinical trials. PLoS ONE 2016, 11, e0161264. Doi: 10.1371/journal.pone.0161264. 466 
12. Gardner, C.; Wylie-Rosett, J.; Gidding, S. S.; Steffen, L. M.; Johnson, R. K.; Reader, D.; 467 
Lichtenstein, A. H. Nonnutritive sweeteners: current use and health perspectives. Diabetes 468 
Care 2012, 35, 1798-1808. 469 
13. Burke, M. V.; Small, D. M. Physiological mechanisms by which non-nutritive sweeteners 470 
may impact body weight and metabolism. Physiol. Behav. 2015, 152 (Pt B), 381-388. 471 
23 
 
14. French Agency for Food, Environmental and Occupational Health and Safety (ANSES) 472 
Opinion on the assessment of the nutritional benefits and risks related to intense 473 
sweeteners. [Online] 2015, 474 
https://www.anses.fr/en/system/files/NUT2011sa0161RaEN.pdf (accessed February 23, 475 
2015). 476 
15. Lange, T.; Scheurer, M.; Brauch, H. J. Artificial sweeteners- a recently recognised class of 477 
emerging environmental contaminants: a review. Anal. Bioanal. Chem. 2012, 403, 2503-478 
2518. 479 
16. Bingham, S. A. Biomarkers in nutritional epidemiology. Public Health Nutr. 2002, 5, 821-480 
827. 481 
17. Landberg, R.; Aman, P.; Friberg, L. E.; Vessby, B.; Adlercreutz, H.; Kamal-Eldin, A. 482 
Dose-response of whole-grain biomarkers: alkylresorcinols in human plasma and their 483 
metabolites in urine in relation to intake. Am. J. Clin. Nutr. 2009, 89, 290-296. 484 
18. Renwick, A.G. (1986) The metabolism of intense sweeteners. Xenobiotica, 1986, 16 485 
(10/11), 1057-1071. 486 
19. Wilson, A. L; Wilkinson, K.; Crews, H. M.; Davies, A. M.; Dick, C. S.; Dumsday, V. L. 487 
Urinary monitoring of saccharin and acesulfame-K as biomarkers of exposure to these 488 
additives. Food Addit. Contam. 1999, 16 (6), 227-238. 489 
20. Roberts, A.; Renwick, A. G.; Sims, J.; Snodin, D. J. Sucralose metabolism and 490 
pharmacokinetics in man. Food Chem. Toxicol. 2000, 38, Suppl. 2, S31-S41. 491 
21. Geuns, J. M. C.; Buyse, J.; Vankeirsbilck, A.; Temme, E. H. M.; Compernolle, F.; Toppet, 492 
S. Identification of steviol glucuronide in human urine. J. Agric. Food Chem. 2006, 54, 493 
2794-2798. 494 
24 
 
22. Logue, C.; Dowey, L.C..; Strain, J.J.; Verhagen, H.; Gallagher, A.M. The potential 495 
application of a biomarker approach to investigate low-calorie sweetener exposure. Proc. 496 
Nutr. Soc. 2016, 75(2), 216-225. 497 
23. Jenab, M.; Slimani, N.; Bictash, M.; Ferrari, P.; Bingham, S. A. Biomarkers in nutritional 498 
epidemiology: applications, needs and new horizons. Hum. Genet. 2009, 125, 507-525.  499 
24. Scheurer, M.; Brauch, H. J.; Lange, F. T. Analysis and occurrence of seven artificial 500 
sweeteners in German waste water and surface water and in soil aquifer treatment (SAT). 501 
Anal. Bioanal. Chem. 2009, 394 (6), 1585-1594. 502 
25. Zygler, A.; Wasik, A.; Namiesnik, J. Analytical methodologies for determination of 503 
artificial sweeteners in foodstuffs. TrAC, Trends Anal. Chem. 2009, 28 (9), 1082-1102. 504 
26. Ordonez, E. Y.; Quintana, J. B.; Rodil, R.; Cela, R. Determination of artificial sweeteners 505 
in water samples by solid-phase extraction and liquid chromatography-tandem mass 506 
spectrometry. J. Chromatogr. A, 2012, 1256, 197-205.  507 
27. Ens, W.; Senner, F.;  Gygax, B. Development, validation and application of a novel LC-508 
MS/MS trace analysis method for the simultaneous quantification of seven iodinated X-509 
ray contrast media and three artificial sweeteners in surface, ground, and drinking water. 510 
Anal. Bioanal. Chem. 2014, 406, 2789-2798. 511 
28. Kuhnle, G. Nutritional biomarkers for objective dietary assessment. J. Sci. Food Agric. 512 
2012, 92, 1145-1149. 513 
29. Bingham, S.; Cummings, J. H. The use of 4-aminobenzoic acid as a marker to validate the 514 
completeness of 24 h urine collections in man. Clin. Sci. 1983, 64, 629-635. 515 
30. Jakobsen, J.; Ovesen, L.; Fagt, S.; Pedersen, A. N. Para-aminobenzoic acid used as a 516 
marker for completeness of 24 hour urine: assessment of control limits for a specific HPLC 517 
method. Eur. J. Clin. Nutr. 1997, 51, 514-519. 518 
25 
 
31. Agilent Technologies. Analysing Synthetic Sweeteners in Waste Water with Robust 519 
Sample Preparation. Application Note (Environmental), [Online] 2011, 520 
http://www.chem.agilent.com/Library/applications/5990-8248EN.pdf. (accessed March 521 
23, 2013).  522 
32. US Food and Drug Administration (FDA) Guidance for Industry, Bioanalytical Method 523 
Validation 2001.   524 
33. Renwick, A. G. The intake of intense sweeteners- an update review. Food Addit. Contam. 525 
2006, 23 (4), 327-338. 526 
34. Yang, D. J.; Chen, B. Simultaneous determination of nonnutritive sweeteners in foods by 527 
HPLC/ESI-MS. J. Agric. Food Chem. 2009, 57, 3022-3027. 528 
35. Christ, O.; Rupp, W. Human experiments with Acetosulfam-14C. Pharmacokinetics after 529 
oral administration of 30mg to three healthy male probands. 1976, Unpublished report. In 530 
Acesulfame Potassium. WHO Food Additives Series 28. [Online] 531 
http://www.inchem.org/documents/jecfa/jecmono/v28je13.htm (accessed June 3, 2015). 532 
36. Ball, L. M.; Renwick, A. G.; Williams, A. G. The fate of [14C] saccharin in man, rat and 533 
rabbit and of 2-sulphamoyl[14C]benzoic acid in the rat. Xenobiotica, 1977, 7, 189-203. 534 
37. Sweatman, T. W.; Renwick, A. G.; Burgess, C. D. The pharmacokinetics of saccharin in 535 
man. Xenobiotica, 1981, 11, 531-540.  536 
38. Renwick, A. G.; Thompson, J. P.; O'Shaughnessy, M.; Walter, E. J. The metabolism of 537 
cyclamate to cyclohexylamine in humans during long-term administration. Toxicol. Appl. 538 
Pharmacol. 2004, 196, 367-380. 539 
39. Bopp, B. A.; Sonders, R. C.; Kesterson, J. W. Toxicological aspects of cyclamate and 540 
cyclohexylamine. Crit. Rev. Toxicol. 1986, 16(3), 213-306. 541 
40. Wheeler, A.; Boileau, A. C.; Winkler, P. C.; Compton, J. C.; Jiang, X.; Mandarino, D. A. 542 
Pharmacokinetics of rebaudioside A and stevioside after single oral doses in healthy men. 543 
Food Chem. Toxicol. 2008, 46, S54-S60. 544 
41. Geuns, J. M. C.; Buyse, J.; Vankeirsbilck, A.; Temme, E. H. M. Metabolism of stevioside 545 
by healthy subjects. Exp. Biol. Med. 2007, 232, 164-173.  546 
26 
 
Figure captions 547 
Figure 1. LC-ESI-MS/MS chromatogram of a single analysis of spiked urine sample depicting the 548 
most intense MRM transition for each compound. (a) acesulfame-k, m/z 162/82, (b) sodium 549 
saccharin, m/z 182/42, (c) sodium cyclamate, m/z 178/80, (d) sucralose, m/z 395/35, (e) steviol 550 
glucuronide, m/z 493/317.  551 
Figure 2. Urinary excretion (a, 24-hour; b, fasting spot) of (i) acesulfame-K, (ii) saccharin, (iii) 552 
cyclamate, (iv) sucralose and (v) steviol following low, medium and high doses which were 553 
consumed in a randomized order. a Doses equated to 0.1% (low), 0.5% (medium) and 10% (high) 554 
of the acceptable daily intake based on a 70 kg person.  555 
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Table 1. General characteristics of acesulfame-K, sodium saccharin, sodium cyclamate, sucralose 
and steviol glucuronide. 
Compound Cas No Sweetnessa Structure Monoisotopic 
mass (Da) 
Acesulfame-K 
 
 
55589-62-3 200 
 
200.95 
Sodium saccharin 
 
 
82385-42-0 300-500 
 
204.98 
Sodium cyclamate 
 
 
139-05-9 30 
 
201.04 
Sucralose 
 
 
56038-13-2 600 
 
396.01 
Steviol 
glucuronide 
 
 
N/Ab N/Ab 
 
494.57c 
a Sweetness relative to sucrose. b N/A, not applicable. c Average molar mass. Da, daltons.  
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Table 2. Method characteristics, limits of detection and quantification and coefficients of determination. 
Compound Retention 
time (min) 
MRM transitions 
(m/z) 
Collision 
energy (eV) 
Internal standard     
(m/z) 
LOD  
(ng/ml) 
LLOQ     
(ng/ml) 
r2 
Acesulfame-K 2.0 162/82a 
162/78 
-21 
-44 
Ace-d4 (166/86) 0.01 10.0 0.9997 
Sodium saccharin 3.8 182/42a 
182/106 
-42 
-24 
Sac-d4 (186/42) 0.06 10.0 0.9994 
Sodium cyclamate 4.7 178/80a 
178/96 
-42 
-32 
Cyc-d11 (189/80) 0.02 10.0 0.9992 
Sucralose 6.7 395/35a 
395/359 
-32 
-14 
Suc-d6 (401/35) 0.40 10.0 0.9969 
Steviol glucuronide 10.4 493/317a 
493/113 
-32 
-30 
Warfarin Na (307/307) 0.01 10.0 0.9991 
a Transition used for quantification. Limit of detection (LOD) defined as a signal to noise ratio of 3:1. Lower limit of quantification (LLOQ) defined as lowest 
amount of an analyte in a sample that can be quantitatively determined with suitable precision and accuracy. r2 for concentration ranges of 10-1000ng/ml. 
MRM, multiple reaction monitoring; Ace-d4, acesulfame-d4 potassium salt; Sac-d4, saccharin-d4; Cyc-d11, cyclamate-d11; Suc-d6, sucralose-d6; Warfarin 
Na, Warfarin sodium. 
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Table 3. General characteristics of participants taking part in the dose-
response study.a 
 Overall Males 
n 10  
Females 
n 11 
P valueb 
Age (years) 25.7 (4.9) 26.3 (3.7) 25.1 (5.8)    0.173 
Height (m)   1.7 (0.09)   1.78 (0.05)   1.64 (0.07) < 0.001 
Weight (kg) 71.4 (11.9) 77.5 (10.6) 65.8 (10.6)    0.021 
Body mass index     
(kg/m2) 
24.7 (3.4) 24.7 (2.8) 24.6 (4.0)    0.947 
Urine volume (ml)       
Time-point 1c 2024 (759) 1859 (736) 2174 (783)   0.355 
Time-point 2c 1957 (865) 1784 (708) 2114 (994)   0.396 
Time-point 3c 2086 (834) 1831 (556) 2319 (995)   0.188 
a Values are mean (SD). 
b Statistical analyses were carried out to investigate differences between males 
and females. Age was assessed with Mann U Whitney test; height, weight, body 
mass index and urine volume were assessed with Independent Samples t-test.  
c Time-points refer to 24-urine collections after each dosing period.  
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Table 4.  Mean urinary excretions of acesulfame-K, saccharin , cyclamate, sucralose and steviol 
following low, medium and high doses of the respective low-calorie sweetener.a 
 0.1% ADI 0.5% ADI 10% ADI P valueb 
24-hour urine sample 
(mg/day) 
n = 14 n = 13 n = 12 
Acesulfame-K  0.59 (0.09)   2.85 (0.30)*  52.56 (5.33)* <0.001 
Saccharin   0.40 (0.32)   1.34 (0.37)*  29.51 (9.72)* <0.001 
Cyclamate   0.12 (0.05)   0.54 (0.13)*  10.99 (2.92)* <0.001 
Sucralose   5.40 (2.07) 5.20 (1.58)   9.23 (3.92)* <0.001 
Steviol  0.23 (0.04)   0.72 (0.29)*  12.70 (5.54)* <0.001 
Spot urine sample    
(µg/g creatinine) 
n = 19 n = 19 n = 19  
Acesulfame-K 455 (836)    1396 (1331)*   31983 (34562)* <0.001 
Saccharin 210 (304)    1171 (1650)*   18408 (15562)* <0.001 
Cyclamate  71 (89)   470 (904)*  7569 (6494)* <0.001 
Sucralose  3453 (6644) 2668 (2210) 5493 (5159)* <0.001 
Steviol 146 (106)   905 (799)*  13913 (13956)* <0.001 
a Values represent means (SD); ADI, acceptable daily intake. Low, medium and high doses represent 0.1%, 0.5% 
and 10.0% of the ADI for a 70 kg person. 
b Freidman Tests carried out to compare means urinary concentrations across all time-points. Wilcoxon Signed 
Rank tests then carried out as post-hoc analysis to determine where the differences were with Bonferroni 
adjustment applied to control for multiple comparisons; as such P value of <0.017 was considered as significant. 
* denotes a statistically significant difference with the immediate lower dose. 
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Figure graphics 
Figure 1  
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Figure 2 
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